There is no current consensus on which treatments should be part of standard, deceased-donor management to improve graft quality and transplantation outcomes. The objective of this systematic review was to evaluate the effects of treatments of the deceased, solid-organ donor on graft function and survival after transplantation.
INTRODUCTION
Due to the persistent shortage of organs available for solid organ transplantation (1) , the transplant community has been searching for possibilities to further expand the donor pool. One way to achieve this is by accepting organs retrieved from older and higher risk donors, without compromising good transplantation outcomes. Improving quality of suboptimal organs from unstable donors after brain death (DBD), older expanded criteria donors (ECD), or from donors after circulatory death (DCD) mandates better assessment and optimisation prior to transplantation. DBD, ECD, and DCD donors have all suffered from cerebral injury, which leads to a profound systemic inflammatory response (2, 3) . Additionally in DBD donors, increased intracranial pressure impairs brain perfusion and causes herniation of the brain stem. This results in the release of catecholamines and a cascade of derangements that lead to endothelial dysfunction and inflammation in the potential grafts-to-be (4) (5) (6) . In addition, the function of the hypothalamus and pituitary gland becomes impaired, which leads to decreased cortisol, triiodothyronine (T3), insulin, and antidiuretic hormone (ADH) plasma levels in the donor (7, 8) . After herniation of the brain stem, a haemodynamically unstable state will follow, which requires fluid resuscitation and often inotropic support. In the DCD donor, there is no catecholamine release, but instead withdrawal of medical support will result in a significant blood pressure drop until circulatory arrest. The period of circulatory arrest is followed by a in most countries medico-legal five-minute no-touch period prior to confirmation of death, which adds extra warm ischaemic injury and threatens the quality of the potential grafts. In addition to these donor-related injuries, the grafts-to-be subsequently endure a period of preservation and cold ischaemia that are further detrimental to the organ quality.
To improve transplant outcomes in solid organ transplantation, an optimised and more organ-protective Intensive Care regimen should be adopted. Such a strategy has increasingly become important in the last decade since donor age and comorbidity of donors have increased significantly in most countries. In the past years, numeral treatment options have been considered in deceased donors aspiring improvement of graft function and survival after transplantation. Unfortunately, clinical implementation has not happened, whilst a lot of controversy still exists about which treatment could actually benefit donor organs potentially improving transplant outcomes.
The purpose of this systematic review is to provide an update on all systematically tested clinical interventions in the deceased donor and their impact on graft function and/or survival following solid organ transplantation. This review will concern any clinical treatment regimen that was carried out in either DBD or DCD donors using either specific drugs, fluids, or procedures to reduce donor organ injury prior to organ preservation and transplantation.
Search methods for identification of studies
This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (9) . Potential RCTs were identified using electronic and manual search strategies. The final electronic literature searches were performed in Pubmed (5 Nov 2016) , Embase (5 Nov 2016) , and the Cochrane library (7 Nov 2016) . The ClinicalTrials.gov register was also searched (7 Nov 2016) to identify unpublished or ongoing trials. The search was limited to RCTs with a highly sensitive search-strategy filter(10). The bibliographies of identified studies and reviews were manually searched for additional trials. A qualified librarian reviewed the final search strategy. The search strategy for each consulted database is available in the supplementary data (Figure S1, Table S1 and S2).
Data extraction and validity assessment
All identified records were screened on title and abstract after removal of duplicates with an algorithm provided by Refworks (ProQuest-LCC, USA). Full articles of selected records were retrieved and assessed for eligibility; disagreements were resolved by consensus. Abstracts not providing information on the study type or outcome parameters were retrieved for fulltext evaluation. Study information was extracted independently by two reviewers. The risk of bias assessment was performed according to the Cochrane risk of bias tool (11) . The assessment of study quality included random sequence generation, allocation concealment, performance bias, detection bias, attrition bias, reporting bias, and "other" bias. Quality assessments were performed independently and disagreements were resolved through discussion.
Data synthesis
Outcome parameters of interest for all transplanted solid organs were: patient and graft survival; development of primary dysfunction, sometimes subdivided in either primary non-function (PNF) or initial poor function; and acute rejection. Organ-specific parameters of interest were: creatinine clearance, serum creatinine, and delayed graft function (DGF) (kidney); aspartate transaminase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), gammaglutamyl transpeptidase (γGT), and bilirubin levels (liver); haemofiltration or haemodialysis requirement, and left ventricular function (heart). Qualitative assessment was performed for single studies that could not be grouped for meta-analyses. For studies that could be grouped, a forest plot was constructed to assess the heterogeneity with the Cochran's Q test and the I 2 -test (considered significant when p <0.1 or I 2 >30%). A random-effects analysis model was applied, followed by the Mantel-Haenszel test to calculate cumulative relative risk (RR) ratios for dichotomous variables. As no more than four studies were included per meta-analysis, funnel plot analyses could not be constructed to distinguish potential asymmetry. All statistical analyses were performed with Review Manager v5.3 (The Cochrane Collaboration 2014).
RESULTS

Literature search and summary of included studies
From 7309 hits in total, 62 studies were assessed. As 29 studies failed to meet our inclusion criteria, a total of 33 articles were included in this systematic review (Figure 1 , Table 1 , Table  S3 ). In addition, we identified 13 trials that were still ongoing or did not yet publish any study results ( Table 2) . As no studies were found that involved an intervention in DCD donors, this systematic review describes only trials on donor management or treatment in DBD donors.
The following treatment strategies for DBD donors were identified: anti-oxidant treatment(12-15), enteral feeding(16), organ retrieval techniques(17,18), haemodynamic support (19) (20) (21) (22) (23) , (24) (25) (26) , mild therapeutic hypothermia (27) , immunosuppressants (28) (29) (30) (31) (32) (33) , ischaemic preconditioning (IPC)(34-41), a lung protection strategy(42,43), and T3 administration(44). Table 1 shows a summary of these included studies, while Table 3 shows the risk of bias for these trials. In 16 studies, the methods for patient selection and allocation concealment were adequately performed or described. Eight studies used a placebo-controlled group, whereas the remaining studies had either non-treatment groups (n=20), or compared the intervention with a conventional treatment strategy (n=5).
Studies that could not be included for meta-analyses
Twenty-two studies (12) (13) (14) (15) (16) (17) (18) (19) (20) (23) (24) (25) (26) (27) (28) (29) (30) 33, 34, (42) (43) (44) were not included for meta-analyses because the type of intervention or outcome parameter could not be compared to other trials included in this review. Of these trials, four studies tested the effects of anti-oxidants on graft function in DBD donors (12) (13) (14) (15) . Both N-acetylcysteine (14) and L-alanyl-glutamine(12) treatment showed no effects following kidney and liver transplantation, respectively. Studies on Ascorbic acid treatment (13) and donor ventilation with sevoflurane(15) showed improved short-term liver function, but did not report effects on patient or graft survival.
Two trials investigated two different hepatic retrieval techniques. Chui et al.(17) showed no differences between single (aortic) or double (aortic and portal) perfusion on liver and kidney transplantation outcomes, whilst D'Amico et al. (18) showed superiority of the double perfusion technique on both short-term liver function and six-month graft and patient survival.
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Systematic review on the treatment of deceased organ donors Six out of eight studies on hemodynamic support of the deceased donor could not be grouped for meta-analyses (19, 20, (23) (24) (25) (26) . Dopamine treatment improved long-term graft survival after heart (20) , but not kidney transplantation (19) , despite a reduced incidence of DGF of renal organ grafts (19) . Prostaglandin I 2 treatment improved short-term liver function, but failed to improve patient or graft survival (23) . Protocolised fluid administration did not alter recipient survival after solid organ transplantation (24) . The use of the colloid hydroxyl-ethyl starch (HES) (of unknown molecular weight) did not affect liver function following transplantation(25); treatment with low molecular weight-HES did increase rates of DGF in HES-treated donors (26) .
Four out of six trials on the use of immunosuppressive drugs in DBD donors could not be clustered. Administration of methylprednisolone and cyclophospamide (29, 30) , cyclophosphamide alone (33) , or prednisolone alone(28) did not improve kidney transplantation outcomes.
Several studies were found to treat liverdonors with IPC, only study investigated five minutes of IPC and showed no benefits of this intervention after liver transplantation.
The remaining trials investigated possible clinical benefits of enteral feeding(16); mild therapeutic hypothermia, cooling of the DBD donor at the Intensive Care Unit from 37°C to 34-35°C (27) ; albuterol(43) or T3(44) administration; and a protective lung ventilation strategy(42). Neither enteral feeding(16), nor albuterol administration(43), nor protective lung ventilation(42) improved survival rates of recipients after heart, lung, liver, or kidney transplantation. Mild therapeutic hypothermia decreased the incidence of DGF after kidney transplantation (27) . Lastly, T3 administration did not improve liver function following transplantation(44).
Studies included for meta-analyses
Eleven studies were identified for further meta-analyses. The meta-analysis on the effects of donor treatment with ADH included 222 participants (21, 22) and showed no difference in the development of DGF after kidney transplantation between treated and untreated DBD donors (Figure 2) . The meta-analysis on donor methylprednisolone treatment versus placebo or no treatment included a total of 183 participants (31, 32) and showed similar acute rejection rates of liver grafts retrieved from donors treated either with or without methylprednisolone (Figure 3) . Ten meta-analyses were included on the effects of 10 minutes of IPC versus no treatment in the liver, with a total of 335 participants from seven trials(35-41). Results show that IPC treatment did not influence one-year (Figure 4A,B) or two-year graft and patient survival (Figure S1A,B) . In the short-term, IPC treatment improved AST levels on day one and international normalised ratio (INR) levels on day three after surgery (Figure 5A,C) , but did not affect INR ( Figure 5B ) or bilirubin levels ( Figure S1E ) one day post-operatively. Also, the incidence of PNF or IPF was not different between treated and untreated grafts (Figure S1C,D) . The risk of bias for included studies is described in Table 3 . In general, the studies included in the meta-analyses were judged to have a relatively high risk of bias.
DISCUSSION
This systematic review provides an update on the existing evidence of treatment strategies that were applied to deceased organ donors aimed to improve graft quality and survival after transplantation. Our meta-analyses found no consistent evidence to support that any specific donor management strategy or treatment in DBD donors benefited outcomes after transplantation. This finding is in line with previous and older reviews published on this topic(45-49).
Anti-oxidants
Brain death and IRI are associated with increased levels of reactive oxygen species (ROS), which play a central role in the deleterious effects following transplantation (50, 51) . Therefore, the use of anti-oxidants to scavenge ROS or support other cellular detoxification mechanisms appears to be an intuitively sound strategy to limit IRI. However, none of the four compounds tested improved survival rates following kidney (N-acetylcysteine) (14) or liver (L-alanylglutamine, ascorbic acid, sevoflurane)(12,13,15) transplantation, even though ascorbic acid (13) and donor ventilation with sevoflurane(15) improved short-term liver function. Recently, a RCT on simultaneous kidney and pancreas transplantations showed that treatment with 600mg alfa-lipoic acid in both donors and recipients resulted in decreased inflammatory markers in the transplanted grafts (52) . These promising results may encourage more trials with anti-oxidant treatment strategies, either in the donor, during graft preservation or at time of reperfusion.
Enteral feeding
For critically ill patients, enteral feeding is the preferred route for nutritional support (53) . However, nutritional support is usually withheld in DBD donors due to suggested negative side effects of both enteral and parenteral feeding. Negative effect of enteral feeding are thought to be impaired nutritional uptake as a result of the inflammatory response taking place in the bowel of DBD donors (54) . Alternatively, parenteral feeding is related to metabolic, infectious, and mechanical complications (55) . The only RCT on this topic compared fasting of the DBD donor to enteral feeding with a diet containing omega-3 polyunsaturated fatty acids, antioxidants, and glutamine. This study shows that transplant outcomes or inflammatory parameters were not different between groups(16). As about 30% of the donors were able to metabolise enteral nutrition without negative side effects(16), enteral feeding appears to be safe method for nutritional support in DBD donors.
Organ retrieval techniques
During organ procurement, there are two techniques to flush-out and perfuse the liver graft. First, a dual perfusion technique flushes the graft via both the aorta and portal vein. This dual technique requires dissection of the liver hilum, which could lead to vessel injuries and is potentially hazardous for preservation of the pancreas and intestines (56) . Alternatively, most centres use single aortic perfusion as a safer and easier alternative, followed by additional back-table flush of the liver after retrieval. The two RCTs that compared these techniques show conflicting results(17,18). Chui et al. (17) found no differences between either technique 123 Systematic review on the treatment of deceased organ donors following liver and kidneys transplantation, while D'Amico et al. (18) found an improved function of marginal livers after dual perfusion. Unfortunately, it is challenging to draw conclusions from these studies as there is a lack data on study design. Chui et al. did not provide a full report on their study design, whilst D'Amico et al. focused primarily on marginal donors, which makes extrapolation of these results to the general donor population difficult. In conclusion, there is currently no strong evidence suggesting superiority of either perfusion technique.
Haemodynamic support
Diabetes insipidus is a common finding amongst DBD donors and may cause haemodynamic instability in the donor due to hypovolaemia and electrolyte disturbances (22) . However, treatment strategies for haemodynamic instability in the donor are frequently implemented based on personal experiences as there is no general consensus on what treatment is most effective. Treatment of hypovolaemia with large volumes of crystalloids has been suggested to cause organ oedema, diminished organ perfusion, and impaired oxygen diffusion in the lungs. Therefore, the use of colloids was introduced to avoid this build-up of extravascular fluids. In DBD donor care, two RCTs studied the effects of donor treatment with the colloid HES. The study by Randell et al.(25) showed no difference in graft function after the administration of HES (unknown molecular weight) compared to saline prior to liver transplantation. However, treatment of DBD donors with low molecular weight HES resulted in harmful short-term effects in kidney grafts (26) . This result has lead to the notion that HES should not be administered to potential kidney donors. However, it should be noted that both studies have a high risk of bias, which may have influenced the results and possibly their interpretation. A different approach to achieve donor euvolaemia is to monitor the pulse pressure variation and correct hypotension according to a protocol that includes fluid or vasopressive drug administration (24) . However, implementation of this protocol failed to improve the recipient survival rate or number of organs transplanted per donor.
Alternatively, five RCTs tested the effects of pharmaceuticals as a means to provide haemodynamic support. Firstly, administration of ADH did not improve graft function ( Figure  2 ), but did result in decreased urine output and, therefore, the need for fluid therapy. Secondly, administration of dopamine in DBD donors had a positive effect on short-term renal graft function (19) , whilst in heart transplantation it improved long-term graft and patient survival (20) . Finally, administration of prostaglandin I 2 improved transaminase levels immediately and one day after liver transplantation, but failed to improve graft survival (23) .
In conclusion, unstable haemodynamic parameters should be treated appropriately with volume replacement and haemodynamic resuscitation. However, volume replacement with HES should be used with caution, especially when kidney donation is considered. Haemodynamic support using dopamine appears to be beneficial in heart and possibly in kidney transplantation. Thus, further studies on the use of dopamine as part of standard donor care and its effects on other organ grafts is desirable.
Hypothermia during donor management
Promising results published by Niemann et al. show that mild therapeutic hypothermia (MTH) of the deceased donor (body temperature of 34-35°C) preserved kidney function during donor management in the Intensive Care Unit, with decreased DGF rates after transplantation. These results are in line with a retrospective cohort study on patients with a myocardial infarction, for whom MTH treatment prior to and during a percutaneous coronary intervention improved survival rates and preserved their renal function (57) . However, these protective effects of MTH could not be reproduced in RCTs on patients with a cardiac arrest (58, 59) or an intracranial aneurysm (60) . Long-term effects of MTH in the deceased donor are eagerly awaited before implementation of this technique can be considered as standard donor care (27) . Furthermore, the study by Niemann only included statically cold stored kidneys, whilst hypothermic machine perfusion has demonstrated to significantly reduce DGF and improve graft survival, especially in older and higher risk donor kidneys (61) . Therefore, the question arises whether both treatment regimens are necessary and which one is more cost-effective. Recently, a new trial has started that will compare the effects of donor MTH with hypothermic machine perfusion on graft function after transplantation (62) .
Immunosuppression
Brain death results in pro-inflammatory changes both systemically and in the organ grafts (4, 5) . In addition, endogenous cortisol levels decrease after the onset of brain death (63) (64) (65) . Therefore, it is conceivable that treating the donor with immunosuppressive drugs could prevent pro-inflammatory changes and improve graft quality, as was suggested in experimental animal studies (66, 67) and a large retrospective cohort study (68) . However, our meta-analysis on the effects of prednisolone treatment in DBD showed no changes in the frequency of acute rejection following liver transplantation (Figure 3) . Furthermore, immunosuppressive drug pretreatment did not improve long-term graft function, nor patient nor graft survival following kidney and liver transplantation (28) (29) (30) (31) (32) (33) , despite a decrease in DBD-related pro-inflammatory changes in these organs. Finally, the short-term benefits of prednisolone treatment in the liver graft as observed by Kotsch et al. (32) , could not be reproduced in a similar study by Amatschek et al. (31) . In conclusion, these studies do not support the routine use of methylprednisolone alone, or in combination with cyclophosphamide, in the management of the deceased donor.
Ischaemic preconditioning
Ischaemia-reperfusion injury (IRI) is an unavoidable deleterious process during organ transplantation in which the organs suffer from a period of ischaemia during procurement, followed by injury inflicted by subsequent reperfusion in the recipient. Murry et al. first introduced the concept of IPC as a method to induce transient ischaemia to prepare organs for subsequent IRI (69) . We identified eight studies on IPC, all performed prior to liver transplantation. Pooled data from our meta-analyses shows a short-term benefit of IPC treatment, evidenced by improved post-operative AST and INR levels. However, long-term effects on patient and graft survival were lacking. The RCT by Franchello et al. reported improved AST levels in a subgroup of marginal donors (> 65 years old and/or with steatosis). Further studies powered to detect changes in short-term survival rates and adjusted for graft quality should be performed to elucidate whether IPC should be included in standard donor 125 Systematic review on the treatment of deceased organ donors care. Furthermore, there are currently several on-going trials investigating remote IPC, a technique where (repetitive) cycles of ischaemia are applied to a remote organ or tissue such as a limb with, consequentially, a possible wider therapeutic timeframe in the donor ( Table 2) .
Lung protection strategies
DBD donors are at increased risk of pulmonary damage caused by increased pulmonary hydrostatic pressure, catecholamine release, and pro-inflammatory changes (70, 71) . However, the optimal lung ventilation strategy in decreased donor care has been a topic of controversy (72) . Conventionally, high tidal volumes (TV) (10-12 mL/kg) were applied to ensure hypocapnia and decrease intracranial hypertension, and combined with low positive endexpiratory pressures (PEEP) (3-5 cm H 2 O) to provide optimal oxygenation (71) . Recent studies on patients with the acute respiratory distress syndrome support an alternative strategy with a low TV and high PEEP, as this strategy appears to have improved outcomes of acute lung injury through reduction ventilation related-injury and prevention of atelectasis (71, 73) . Based on these studies, Mascia et al. implemented this protective ventilation strategy with low TV (6-8 mL/kg) and high PEEP (8-10 cm H 2 O) in DBD donor care (71) . Even though this ventilation strategy did not improve patient survival, there was a significant increase from 27% to 54% in the number of lungs transplanted(42). These data have aided in the implementation of this protective lung ventilation strategy as the preferred ventilation strategy for deceased donors, according to the recent guidelines from the Eurotransplant region as well as the American Thoracic Society(74,75).
An alternative strategy to improve the quality of donor lungs is the use of beta-2-adrenergic agonists, which increase the rate of fluid clearance from the lungs, and as such, can potentially lower the risk of pulmonary oedema and subsequent infiltrates, and improve oxygenation capacity (76) . However, treatment of the donor with aerosolised albuterol did not improve lung function, recipient survival, or lung utilisation rates(43). A subgroup analysis that included only marginal donor lungs even indicated lower lung utilisation in the albuterol-treated group. Finally, albuterol treatment resulted in a lower kidney utilisation rate of 77% vs. 88% in the placebo-treated group. As such donor treatment with albuterol does not seem to improve lung function and may have a negative impact on marginal donor lungs as well as kidney grafts.
Triiodothyronine
Brain death causes ischaemia of the brain and subsequent cessation of the hypothalamicpituitary axis. As a result, plasma levels of the active thyroid hormone T3 diminish in a matter of hours, whereas variable levels of levothyroxine (T4), reverse T3, and thyroid stimulating hormone have been observed(45). A large retrospective cohort of 66,629 donors suggested that T3 treatment improved the haemodynamic profile of donors and increased the number of organs transplanted (77) . However, the only RCT that has evaluated post-transplantation graft function failed to show any effects of T3 therapy on liver function(44). During the screening process, we did identify nine RCTs that assessed effects of T3 treatment on haemodynamic stability in the donor. Of these studies, none found any differences in haemodynamic donor parameters or inotropic needs(44, [78] [79] [80] [81] [82] [83] [84] [85] . As a result, the current national guidelines of NHSBT (National Health Service Blood and Transplant) in the UK no longer advise administration of a rather costly T3 as part of the DBD donor management.
Limitations of this review
Firstly, the number of RCTs that investigated treatment strategies in the donor and their impact on graft function and survival after transplantation is limited. Furthermore, as our search strategy focused on donor treatment only, potentially promising treatment strategies of the graft after procurement and during preservation were excluded that may be of a pretransplant treatment potential. In addition, the studies we did include were often performed with a low number of participants and sometimes underpowered to detect changes in the outcome parameters as stipulated in this review. Consequentially, potential effects on organ function or survival might have been missed. The few number of studies also limited us from assessing the risk of publication bias. Therefore, drawing conclusions from these studies is risky, particularly when grouping for meta-analyses was not possible. Lastly, we realise that several promising treatment strategies published in relevant animal models are not included in this article. However, we believe that these studies were outside the scope of this review, as interpretation of these results are not yet influential in clinical decision making in deceased donor care.
Authors' conclusions
The current global shortage of suitable donor organs and often uncertainty which organ to accept or decline, underlines the need for optimisation of deceased donor care. Treatment strategies aim at reducing the detrimental effects of haemodynamic, hormonal, inflammatory, and metabolic disturbances prior to organ retrieval. Better conditioning of the grafts-to-be and reducing, or even preventing, donor-related injury prior to preservation and transplantation have become important goals to transplant higher risk donor organs, without compromising outcomes after transplantation. Unfortunately, current donor management protocols may vary considerably per centre and are based on low-level evidence. In this systematic review, we could not find consistent evidence supporting that any individual treatment that has been tested until now will protect donor organs or improve survival after transplantation. More organised and defined RCTs are required to identify and validate possible benefits of innovative treatments before clinical implementation can be recommended as part of standard donor care. We feel that a concerted action between professionals in Intensive Care and organ transplantation is needed to gain better insight and stimulate clinically relevant interventions in DBD donors.
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Figure 2. Meta-analysis for antidiuretic hormone treatment in kidney transplantation
A forest plot comparing the effects of antidiuretic hormone treatment versus placebo or no treatment on delayed graft function, defined as the need for haemodialysis within two weeks post kidney transplantation.
Figure 3. Meta-analysis for methylprednisolone treatment in liver transplantation
A forest plot comparing the effects of methylprednisolone treatment versus placebo or no treatment on the incidence of acute rejection within one to six months after liver transplantation. one-year patient survival.
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Figure S1. Other meta-analyses for ischaemic preconditioning (IPC) treatment in liver transplantation
Forest plot comparing the effects of 10 minutes of IPC treatment in liver transplantation on: A. two-year graft survival; B. two-year patient survival; C. the incidence of liver primary non-function; D. the incidence of initial poor function; E. the difference in bilirubin levels one day after transplantation.
